BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study
BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study
簡介-經皮冠狀動脈介入治療研究的最新藥物
Nov 4 (Reuters) - Medicure Inc MPH.V :
路透11月4日電-Medicure Inc MPH.V:
* MEDICURE ANNOUNCES THAT THE SHORTENED AGGRASTAT® VERSUS INTEGRILIN® IN PERCUTANEOUS CORONARY INTERVENTION (SAVI-PCI) STUDY HAS MET ITS PRIMARY ENDPOINT
*Medure宣佈,縮短的Aggrastat®與Integrlin®In Perkins冠狀動脈介入(SAVI-PCI)研究已達到其主要終點
Source text for Eikon: ID:nCNW6qSwXa Further company coverage: MPH.V
Eikon的源文本:ID:nCNW6qSwXa進一步的公司報道:MPH.V
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com;)